Converting open heart surgery to
a transcatheter procedure.
Bringing new hope to millions
of patients
The Problem
Millions of heart failure patients are without a viable treatment
Severe functional mitral regurgitation (FMR) affects millions of patients. Due to high surgical risks, only a small percentage of patients undergo open-heart valve surgery. Nearly half of the remaining patients, who are treated with medication only, will die within two years.
VALFIX Solution
Converting open-heart valve surgery to a transcatheter procedure
VALFIX system offers a solution to the millions of patients currently without viable treatment.
VALFIX’s innovative and game-changing system, powered by a proprietary robotic interface, enables cardiologists to perform transcatheter mitral valve repair procedures with enhanced precision and control, alleviating heart failure symptoms, improving quality of life, and saving lives
Main Advantages
Minimally Invasive Procedure
Short
Procedure
Time
Easy
Adoption By
Cardiologists
Backed By Leading
Surgeons & Cardiologists
Why VALFIX is a game changer
About Us
VALFIX was founded with a mission to heal hearts and save lives by experienced medical device entrepreneurs and a leading interventional cardiologist
VALFIX’s technology responds to the current large and clinically significant unmet need.
VALFIX’s proprietary technology has passed proof of concept and is moving forward to clinical trials.